The Patient-Provider Relationship Study

Researchers of a phase 3 trial aimed to determine whether statins, specifically pitavastatin, could reduce the incidence of major adverse cardiovascular events among HIV patients, as the risk of cardiovascular disease is increased in those with HIV infection.

Managed Healthcare Executive's Managing Editor Peter Wehrwein, and Editor Briana Contreras, had a discussion in July with Mostafa Kamal, president and CEO of Prime Therapeutics, an organization in which Kamal acquired this position that same month.

Animal studies of a new compound, which can be delivered by eye drop, have found that it can reverse epigenetic changes that lead to wet age-related macular degeneration.

Briana Contreras, an editor of Managed Healthcare Executive, had the pleasure of catching up with MHE Editorial Advisory Board Member, Ateev Mehrotra, MD, MPH, who is a professor of healthcare policy at Harvard Medical School and an Associate Professor of Medicine and Hospitalist at Beth Israel Deaconess Medical Center.

ICER has weighed in on two of the 10 drugs selected for negotiations: Eliquis and Xarelto, which are among Medicare Part D’s highest spending drugs.

Even though the Inflation Reduction Act will require plans to justify formulary placement of negotiated drugs, payers have more of an incentive to steer patients to lower-cost alternatives.